Gilead Reports Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for Treatment of Chronic Hep C
November 11, 2014 at 08:06 AM EST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of ...